Dr. Wang is a clinical geneticist with accreditations from the American Board of Medical Genetics (ABMG) and the American Board of Internal Medicine (ABIM). She also has considerable experience in the fields of molecular biology, biochemistry and genomics. She has 20 years of experience in genetic conditions. Her work focuses on evaluation of hereditary cancer, interpretation of genetic test results, cancer screening for individuals with hereditary risk, and comprehensive care for individuals with complex hereditary tumor syndromes, such as neurofibromatosis, tuberose sclerosis, Cowden syndrome, Li-Fraumeni syndrome and von Hippel-Lindau disease. Dr. Wang directs GeneHome clinic. Assisted by an experienced nurse practitioner, she designs cancer screening strategies based on national practice guidelines and tailored to the patient’s particular situation. Not only Dr. Wang evaluates, examines and educates patients and their families, but she also coordinates complex cancer screening schedules and refers patients for further diagnostics and treatment when needed. Dr. Wang created and directs the first multi-disciplinary neurofibromatosis clinic in Florida dedicated to adult patients. The Moffitt NF clinic offers its patients and family members educational and counseling services, as well as a variety of genetic testing options and comprehensive evaluations. The comprehensive and coordinated care is made possible by an extended team of specialists dedicated to neurofibromatosis. The Moffitt NF clinic is certified by CTF NF foundation as a part of NFCN (NF Clinic Network). Besides clinical care, Dr. Wang also engages in research aimed at advancing the strategies to monitor, screen and optimize the timing of intervention for hereditary cancer/tumor syndromes. She has characterized the histological and molecular features of breast cancer in women with neurofibromatosis type 1.
Education & Training
Detroit Medical Center - Clinical Medical Genetics
Wei G, Kumar A, Lee MC, Wang X. Influential Factors on Risk-reduction Mastectomy in a High-risk Breast Cancer Population With Genetic Predispositions. Clin Breast Cancer. 2021 Jan. Pubmedid: 33712364.
Berry DK, Wang X, Michalski ST, Kang HC, Yang S, Creelan BC, McLeod HL, Hicks JK. Clinical Cohort Analysis of Germline EGFR T790M Demonstrates Penetrance Across Ethnicities and Races, Sexes, and Ages. JCO Precis Oncol. 2020 Mar.4. Pubmedid: 34164592. Pmcid: PMC8216676.
Galati MA, Hodel KP, Gams MS, Sudhaman S, Bridge T, Zahurancik WJ, Ungerleider NA, Park VS, Ercan AB, Joksimovic L, Siddiqui I, Siddaway R, Edwards M, de Borja R, Elshaer D, Chung J, Forster VJ, Nunes NM, Aronson M, Wang X, Ramdas J, Seeley A, Sarosiek T, Dunn GP, Byrd JN, Mordechai O, Durno C, Martin A, Shlien A, Bouffet E, Suo Z, Jackson JG, Hawkins CE, Guidos CJ, Pursell ZF, Tabori U. Cancers from Novel Pole-Mutant Mouse Models Provide Insights into Polymerase-Mediated Hypermutagenesis and Immune Checkpoint Blockade. Cancer Res. 2020 Dec.80(24):5606-5618. Pubmedid: 32938641. Pmcid: PMC8218238.
Miller DT, Cortés-Ciriano I, Pillay N, Hirbe AC, Snuderl M, Bui MM, Piculell K, Al-Ibraheemi A, Dickson BC, Hart J, Jones K, Jordan JT, Kim RH, Lindsay D, Nishida Y, Ullrich NJ, Wang X, Park PJ, Flanagan AM. Genomics of MPNST (GeM) Consortium: Rationale and Study Design for Multi-Omic Characterization of NF1-Associated and Sporadic MPNSTs. Genes (Basel). 2020 Apr.11(4). Pubmedid: 32252413. Pmcid: PMC7231181.
Wang X, Brzosowicz JP, Park JY. Response to Roberts et al. 2018: cohort ascertainment and methods of analysis impact the association between cancer and genetic predisposition - the tale of breast cancer risk and Lynch syndrome genes MSH6/PMS2. Genet Med. 2019 Sep.21(9):2156-2157. Pubmedid: 30816297.
Wang X, Chitale D. HER2 Expression in NF1 Breast Cancer-Response. Cancer Prev Res (Phila). 2019 Mar.12(3):197-198. Pubmedid: 30792347.
Wang X, Kallionpää RA, Gonzales PR, Chitale DA, Tousignant RN, Crowley JP, Chen Z, Yoder SJ, Blakeley JO, Acosta MT, Korf BR, Messiaen LM, Tainsky MA. Germline and Somatic NF1 Alterations Are Linked to Increased HER2 Expression in Breast Cancer. Cancer Prev Res (Phila). 2018 Oct.11(10):655-664. Pubmedid: 30104415. Pmcid: PMC6905494.
Wang X, Teer JK, Tousignant RN, Levin AM, Boulware D, Chitale DA, Shaw BM, Chen Z, Zhang Y, Blakeley JO, Acosta MT, Messiaen LM, Korf BR, Tainsky MA. Breast cancer risk and germline genomic profiling of women with neurofibromatosis type 1 who developed breast cancer. Gene Chromosome Canc. 2018 Jan.57(1):19-27. Pubmedid: 28891274. Pmcid: PMC7771338.
Wang X, Levin AM, Smolinski SE, Vigneau FD, Levin NK, Tainsky MA. Breast cancer and other neoplasms in women with neurofibromatosis type 1: a retrospective review of cases in the Detroit metropolitan area. Am J Med Genet A. 2012 Dec.158A(12):3061-3064. Pubmedid: 22965642. Pmcid: PMC3505236.
Wooderchak W, Gedge F, McDonald M, Krautscheid P, Wang X, Malkiewicz J, Bukjiok CJ, Lewis T, Bayrak-Toydemir P. Hereditary hemorrhagic telangiectasia: two distinct ENG deletions in one family. Clin Genet. 2010 Nov.78(5):484-489. Pubmedid: 20412114.
Wang X, Jakobs C, Bawle EV. D-2-Hydroxyglutaric aciduria with absence of corpus callosum and neonatal intracranial haemorrhage. J Inherit Metab Dis. 2003.26(1):92-94. Pubmedid: 12872850.
Wang X, Hansen SK, Ratts R, Zhou S, Snook AJ, Zehring W. Drosophila TFIIE: purification, cloning, and functional reconstitution. Proc Natl Acad Sci U S A. 1997 Jan.94(2):433-438. Pubmedid: 9012800. Pmcid: PMC19529.
The Provider Rating is an average of all responses to specific care provider-related
questions from our nationally-recognized
Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our
Patient Satisfaction Survey . The comments are submitted by patients
and reflect their views and opinions. Patients are de-identified for confidentiality and
We post both positive and negative comments from the surveys. We do not post comments
that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may
risk the privacy of our patients.
A “[…]” in the comments below indicates de-identified patient information or comments that
are unrelated to the patient’s experience with the visit to the provider, such as
comments related to another provider, about the survey itself, or otherwise completely
Not all providers will have a star rating or comments. In order to ensure accuracy of our
ratings, we only display ratings for providers who have a minimum of 30 completed from
the previous 12 months.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey
Patient Satisfaction Survey. If a provider does not have ratings or comments listed it
can be for several reasons, including:
The provider has not yet received the minimum number of patient satisfaction surveys
to be eligible for display. We require a minimum of 30 surveys before we post
results to ensure that the rating is statistically reliable and a true reflection of
He or she may be a researcher or other type of provider that does not see patients.
The provider practices in a specialty or office that does not use the specified
surveys currently used for these ratings.
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub